Technologies
Each platform below starts from the same question: what complication follows this device or procedure, and can a pharmaceutical delivered from the device itself prevent it?
The platform Angiotech is best known for: pairing an intravascular scaffold with a controlled-release drug coating so therapy acts precisely where the vessel was treated. This work helped establish drug elution as a standard concept in cardiovascular medicine.
Our most influential contribution. Formulating and controlling paclitaxel release from a device surface influenced later generations of combination medical technologies well beyond the coronary artery.
Sutures, meshes and closure products designed to reduce surgical-site complications, with drug-carrying options where infection or scarring risk is highest.
Devices that deliver therapy locally during an interventional procedure, concentrating dose at the target and limiting systemic exposure.
Sustained-release approaches for ocular tissue, where dosing precision and device tolerability determine outcomes.
Polymer, coating and surface science that governs how an implanted device interacts with living tissue over months and years.
